We uphold rigorous standards through EU-GMP certification, independent testing, and continuous technological evaluations. Our team’s strong pharmaceutical and medicinal-cannabis expertise guarantees the highest safety and quality levels.

The cannabis industry increasingly demands non-destructive decontamination. Our cold plasma technology effectively eliminates contaminants while preserving the plant’s natural profile—ideal for cultivators, wholesalers, and producers.

We serve B2B clients in both medical and recreational sectors. Our main customers include cannabis cultivators, raw-material wholesalers, and producers in need of safe, efficient decontamination solutions.

With nearly 80 % of production capacity already pre-sold, we’re scaling by launching 25 service centers in key regulated markets. Strategic partnerships and signed LOIs ensure stable monthly demand.

Our operational launch is funded through a €1.4 million bank loan and a €600 k strategic investment. With over 90 % of capacity booked for three-shift operations, we are poised for rapid expansion.

While regulatory risks exist—as in any emerging market—our patented tech and growing demand mitigate these. This positions us as a high-growth opportunity in cannabis decontamination.

Independent tests confirm our process preserves cannabinoids, terpenes, taste, and aroma—unlike other methods that often degrade product quality.

Our leadership team includes seasoned experts from cannabis and pharmaceutical industries, with proven success in scaling operations and achieving EU-GMP certification.

We’ve completed technology assessments, market testing, and secured binding contracts. Our facilities, scalable machines, and successful independent tests ensure we’re launch-ready.

Market entry in Canada is targeted for late 2024, with an EU pharmaceutical rollout planned for 2025—aligned with regulatory strategies and industry demand.

We currently hold scientific-use cannabis handling approvals and are pursuing further licenses, including GMP validation, to meet stringent standards.

Our system can process 12 tons annually under a three-shift operation, with potential for significant expansion as market demand rises.

Yes. By eliminating microbial threats without harming the plant, cold plasma extends shelf life while maintaining potency and safety.

Cold plasma operates at near-room temperatures using safe reactive species that deactivate microbes while preserving THC, terpenes, and other key compounds.

Our process is more energy-efficient and gentler on the product than irradiation, leading to better quality and long-term cost savings.

Cold plasma is ionized gas at low temperatures used for sterilization in pharmaceutical and food industries—proving its safety and effectiveness in multiple sectors.